ArticleScientific reports2025
Identification of early warning biomarkers for type 4 cardio-renal syndrome based on bioinformatics analysis and secreted proteins.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A bibliometric analysis of artificial intelligence applications in heart failure.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic kidney disease (CKD) can induce chronic heart failure (CHF), a condition referred to as type 4 cardiorenal syndrome (CRS4). The pathophysiological mechanisms remain unclear, and suitable early warning biomarkers for CHF in CKD patients are lacking. A total of 258 CHF key genes and 383 CKD-related secreted proteins were identified through differential expression analysis and WGCNA. PPI analysis revealed 81 genes as potential pathogenic genes related to CRS4. Enrichment analysis of these pathogenic genes highlighted pathways involved in cytokine activity, extracellular matrix remodeling, and immune response. Three machine learning algorithms identified two hub genes (MME and SERPINF1) as potential biomarkers for CHF, and a nomogram model was constructed. ROC analysis demonstrated that the model achieved an AUC greater than 0.80 in both the CHF merged dataset and two external cohorts. Furthermore, immune cell infiltration analysis indicated a correlation between these biomarkers and the infiltration scores of fibroblasts, CD8 T cells, and mast cells in CHF. Finally, our clinical cohort validated the expression patterns of these two biomarkers in serum, with the diagnostic model achieving an AUC of 0.880. CKD may promote the progression of CHF through proteins secreted by the kidneys and blood cells. MME and SERPINF1 may serve as potential biomarkers for CHF in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.